Treatment options after brigatinib/brigatinib resistance

Brigatinib is a targeted therapy for non-small cell lung cancer (NSCLC) caused by ALK (tyrosine kinase) mutations. However, like many other targeted drugs, resistance to brigatinib may develop during long-term use. Once resistance occurs, the therapeutic effect of the original drug will be greatly reduced, and then it is necessary to consider adjusting the treatment plan.

The emergence of drug resistance usually means that cancer cells have developed mechanisms to resist the drug. This may be due to various reasons such as genetic mutations, changes in drug metabolism pathways, or changes in the tumor microenvironment. Therefore, the treatment strategy after drug resistance needs to comprehensively consider the specific situation of the patient and the characteristics of the tumor.

A common post-resistance treatment option is to switch to another targeted drug. Currently, there are a variety of targeted drugs targeting the ALK gene available on the market. Doctors can choose a suitable alternative drug based on the patient's resistance mechanism and genetic test results. The advantage of this strategy is that it is highly targeted and can directly act on specific targets of tumor cells. However, it should be noted that cross-resistance between different drugs may exist, so the choice of alternative drugs needs to be carefully evaluated.

In addition to replacing targeted drugs, immunotherapy is also an important treatment option after drug resistance. Immunotherapy has unique advantages by activating the patient's own immune system to attack tumor cells. For patients who are resistant to brigatinib, immunotherapy drugs such as immune checkpoint inhibitors can be considered. These drugs can restore the function of the immune system and enhance the inhibitory effect on tumor cells.

In addition, chemotherapy is also an alternative after drug resistance. Although chemotherapy has serious side effects, it may be an effective treatment for some patients with severe drug resistance. Doctors can develop a personalized chemotherapy plan based on the patient's specific situation and the characteristics of the tumor.